Related Experiment Video
Updated: Aug 6, 2026

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
Nelarabine: efficacy in the treatment of clinical malignancies
Andrew M Roecker1, Jeffery C Allison, David F Kisor
1Ohio Northern University College of Pharmacy, 525 South Main Street, Department of Pharmacy Practice, Ada, OH 45810, USA. a-roecker@onu.edu
Abstract:
Nelarabine is a nucleoside analog prodrug of 9-beta-D-arabinofuranosylguanine. Nelarabine is indicated for the treatment of adult and pediatric patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma whose disease has not responded to, or has relapsed after treatment with, at least two chemotherapy regimens. Nelarabine was granted Orphan Medical Product Status in Europe in June 2005, and accelerated approval by the US FDA in October 2005. The most common adverse events associated with nelarabine are neurotoxic in nature and have been dose-limiting.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Antiprotozoal Agents
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules